Inflammatory cytokines following diethylcarbamazine (DEC) treatment of different clinical groups in lymphatic filariasis (Q30846997)

27 June 2017

Inflammatory cytokines following diethylcarbamazine (DEC) treatment of different clinical groups in lymphatic filariasis (English)

1 reference

27 June 2017

0 references

1 reference

Haarbrink M

1

1 reference

27 June 2017

Terhell AJ

2

1 reference

27 June 2017

Abadi GK

3

1 reference

27 June 2017

Mitsui Y

4

1 reference

27 June 2017

Yazdanbakhsh M

5

1 reference

27 June 2017

1 November 1999

1 reference

Transactions of the Royal Society of Tropical Medicine and Hygiene

27 June 2017

1 reference

27 June 2017

93

1 reference

27 June 2017

665-672

1 reference

27 June 2017

6

1 reference

The potential biological and clinical significance of the soluble tumor necrosis factor receptors

27 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2899%2990093-7

7 January 2021

The acute phase response

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2899%2990093-7

7 January 2021

Histopathological, lymphoscintigraphical, and immunological changes in the inguinal lymph nodes of rhesus monkeys during the early course of infection with Brugia malayi

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2899%2990093-7

7 January 2021

Lipopolysaccharide toxicity-regulating proteins in bacteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2899%2990093-7

7 January 2021

Adverse reactions following diethylcarbamazine (DEC) intake in 'endemic normals', microfilaraemics and elephantiasis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2899%2990093-7

7 January 2021

Interleukin 6 is involved in interleukin 1-induced activities

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2899%2990093-7

7 January 2021

Differential decline in filaria-specific IgG1, IgG4, and IgE antibodies in Brugia malayi-infected patients after diethylcarbamazine chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2899%2990093-7

7 January 2021

C-reactive protein in patients with lymphatic filariasis: increased expression on lymphocytes in chronic lymphatic obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2899%2990093-7

7 January 2021

Development of a competitive enzyme-linked immunosorbent assay for diethylcarbamazine

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2899%2990093-7

7 January 2021

Interleukin 10 in febrile patients and patients with sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2899%2990093-7

7 January 2021

C-reactive protein and interleukin-6 are elevated in onchocerciasis patients after ivermectin treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2899%2990093-7

7 January 2021

The lymphatic pathology of chronic Brugia pahangi infection in the dog.

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2899%2990093-7

7 January 2021

Interleukin-6 and tumor necrosis factor in the pathogenesis of adverse reactions after treatment of lymphatic filariasis and onchocerciasis

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2899%2990093-7

7 January 2021

Kinetics of circulating human IgG4 after diethylcarbamazine and ivermectin treatment of bancroftian filariasis

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2899%2990093-7

7 January 2021

A monoclonal antibody-based enzyme immunoassay for detecting parasite antigenemia in bancroftian filariasis

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2899%2990093-7

7 January 2021

Serum Interleukin-6 Levels and Adverse Reactions to Diethylcarbamazine in Lymphatic Filariasis

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2899%2990093-7

7 January 2021

Efficacy of diethylcarbamazine in eradicating infection with lymphatic-dwelling filariae in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0035-9203%2899%2990093-7

7 January 2021

10.1016/S0035-9203(99)90093-7

Identifiers

DOI

1 reference

27 June 2017

1 reference